INTRODUCTION This study was designed to compare outcomes among patients by race and ethnicity in the post-covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment era. METHODS A nationwide electronic health record (EHR)-derived de-identified database was utilized that included patients diagnosed with CLL from 2013 to 2022 who received systemic therapy for their disease. Use of cBTKi therapy, time to next treatment or death (TTNT-D), and overall survival (OS) were compared by race in unadjusted (Kaplan-Meier method) and adjusted analyses (Cox proportional hazards regression). RESULTS This study included 4,572 White (71.8%) and 558 Black (8.8%) patients with CLL; 270 were Hispanic or Latino (4.2%). Patients who were Black were significantly younger, more were female, had later stage disease, were of lower socioeconomic status (SES), and were more likely to have unmutated immunoglobulin heavy chain gene (IGHV) and to have received cBTKi therapy than White patients (all p ≤ 0.002). SES was also significantly different by ethnicity. TTNT-D and OS were not different by race in either unadjusted or adjusted analyses (all p > 0.05). CONCLUSION In unadjusted and adjusted analyses, TTNT-D and OS were not different by race. These data did not identify racial healthcare disparities in the era following the introduction of cBTKi therapy despite differences in baseline characteristics.

中文翻译：

---

美国诊断患有 CLL/SLL 的患者的种族和民族特征及结果。


简介 本研究旨在比较后共价布鲁顿酪氨酸激酶抑制剂 (cBTKi) 治疗时代按种族和民族划分的患者的结局。方法 利用全国电子健康记录 (EHR) 衍生的去识别化数据库，其中包括 2013 年至 2022 年诊断为 CLL 并接受系统治疗的患者。在未调整（Kaplan-Meier 方法）和调整分析（Cox 比例风险回归）中按种族比较 cBTKi 疗法的使用、下次治疗或死亡时间 (TTNT-D) 以及总生存期 (OS)。结果 这项研究包括 4,572 名白人 (71.8%) 和 558 名黑人 (8.8%) 慢性淋巴细胞白血病患者； 270 人是西班牙裔或拉丁裔（4.2%）。与白人患者相比，黑人患者明显更年轻，女性较多，患有晚期疾病，社会经济地位 (SES) 较低，并且更有可能具有未突变的免疫球蛋白重链基因 (IGHV) 并接受 cBTKi 治疗。所有 p ≤ 0.002)。不同种族的社会经济地位也存在显着差异。在未调整或调整的分析中，TTNT-D 和 OS 因种族而异（所有 p > 0.05）。结论 在未经调整和调整的分析中，TTNT-D 和 OS 因种族而异。尽管基线特征存在差异，但这些数据并未确定 cBTKi 疗法引入后时代的种族医疗保健差异。